PrEP access trial aims to eliminate HIV transmission

GPs in NSW and Victoria will be able to provide more high-risk people with HIV pre-exposure prophylaxis (PrEP) therapy under ambitious new schemes that aim to eliminate HIV transmission.

A new clinical trial in NSW will expand access to the antiviral emtricitabine and tenofovir disoproxil (Truvada) for prophylaxis from 300 to 3700 people, with much of the prescribing to be done by GPs.

The EPIC trial, co-ordinated by the Kirby Institute at the University of NSW, has the ambitious target of reducing new HIV infections by half within two years and to "virtually eliminate" HIV